Introduction
The utility of the Herpes simplex thymidine kinase (HSVtk) gene for the treatment of tumors was first proposed by Moolten in 1986 . 1 In addition to thymidine, the HSVtk enzyme will phosphorylate nucleoside analogs such as ganciclovir (GCV), which allows incorporation of these analogues into replicating DNA. The incorporated drug prevents DNA strand elongation that ultimately leads to cell death. Cells that are engineered to express HSVtk exhibit increased sensitivity to ganciclovir as compared with parental cells due to the relative inability of the cellular thymidine kinase enzyme to use ganciclovir as a substrate. 2 Following reverse transcription, murine retroviruses integrate randomly into the target cell genome, a process requiring host DNA replication. [3] [4] [5] Therefore, only actively dividing cells are targets for gene transfer by murine retroviral vectors. This feature of murine retroviral vectors has been exploited in developing potential treatments for cancers of the central nervous system, specifically glioblastoma multiforme. Since gene transfer by murine retroviral vectors is limited to actively dividing cells and there are few non-tumor cells dividing in In addition to improved gene transfer to tumor cells, continued vector production may result in increased systemic exposure to retroviral vectors and potential gene transfer to distal tissues. Biological monitoring of patients enrolled in these clinical trials has demonstrated that vector sequences can be detected occasionally in circulating peripheral blood leukocytes. 8 Vector sequences have also been detected in autopsy specimens from brain tissue, liver, kidney and lung specimens. 9 Importantly, in these studies, vector sequences have not been detected in any gonadal specimens from 22 patients (10 female; 12 male) evaluated to date. While these clinical data are reassuring, the limited sample size does not provide sufficient information for determining the potential risk of vector distribution to unintended tissues and organs. Therefore, two rat studies were conducted to provide additional information regarding potential target organs for retroviral gene transfer following administration of vector producer cells.
Results
A detailed description of the study designs is provided in Materials and methods and summarized in Table 1 . Both the HSVtk and ENV PCR assays were validated before sample analysis (Table 2) . Genomic DNA isolated from tissues collected from naive rats was used for assay validation. A false positive rate of 0.33% was observed using unspiked DNA for the HSVtk PCR assay. To determine the limit of detection for the HSVtk PCR assay, naive rat genomic DNA was spiked with one or 10 copies of target DNA; 67% of the one copy samples were detected and 100% of the 10 copy samples were detected ( Table 2) . These results are in agreement with the Poisson distribution indicating single copy sensitivity of this assay. Furthermore, there was no evidence of tissue-specific interference in this assay. Similar results were obtained for the ENV PCR assay, although a more limited number of samples were analyzed. On the basis of these validations, the sensitivity of both assays is claimed to be 10 or greater vector copies per 500 000 cells with 99.99% confidence.
A total of 160 tissue samples was collected from negative control rats that were injected with PLA via subcutaneous or intracerebral routes and analyzed by HSVtk PCR. The analysts were blinded as to the identity of the samples being tested. Vector was not detected in any of the 165 negative control samples, 120 of which were obtained from subcutaneously injected rats and 45 from intracerebrally injected rats. These results demonstrate that the HSVtk PCR assay was specific and could be performed with minimal risk of contamination (Table 3) . Interestingly, of the 165 tissues collected from negative control rats, two yielded a positive result in the first HSVtk PCR assay, but were negative upon retesting (data not shown). Using the retest strategy described, these samples were reported as negative for the presence of vector (HSVtk) sequences. The overall frequency of tissues positive for either vector or VPCs was low regardless of material administered (VPCs or [Vector]) or route of administration (subcutaneous or intracerebral) ( Table 3 ). An increase in the frequency of vector positive tissues was observed when higher doses of VPCs (3.5% versus 7.6%) or [Vector] (1.7% versus 8.6%) was injected subcutaneously. A similar dose-related increase was not observed when VPCs were injected intracerebrally (24.4% versus 28.2%). The assay results of different tissues are shown in Table 4 . Vector sequences were detected most frequently at the site of injection when VPCs or [Vector] were administered by the subcutaneous or when VPCs were administered by the intracerebral route.
[Vector] was not injected intracerebrally in rats as this was not an anticipated clinical application.
Subcutaneous administration resulted in a dose-dependent increase in the frequency of HSVtk positive injection site samples with both VPCs and [Vector] (Table 4) . When VPCs were injected subcutaneously, two of 10 ani- The frequency of positive tissues is shown as the number of tissues positive for either vector (HSVtk PCR) or VPCs (ENV PCR) out of the total number of tissues analyzed. Only tissues that were positive in HSVtk PCR evaluations were tested in ENV PCR assays.
observed in these positive distal tissues. Three of four animals that had positive lymph node samples when injected with either VPC or [Vector] at the higher dose had positive skin (site of injection) samples. The positive lung sample was detected in one male receiving the higher dose of VPC. This animal also had a positive skin (site of injection) sample. Vector was detected in a single testis sample from an animal that had been injected subcutaneously with VPCs at the lower dose (1×). Interestingly, this sample was obtained from an animal that also had a positive contralateral skin sample. In contrast to animals with positive lymph node or lung samples, this animal was not positive at the site of injection. Furthermore, at a 100-fold higher dose, vector was not detected in gonadal tissues.
As with subcutaneous injection of VPCs, the most frequent positive tissue following intracerebral injection of VPCs was the site of injection. The only distal tissue found to contain vector sequences following intracerebral injection of VPCs was the mandibular lymph node. All other tissues, including gonads, were negative.
Since a positive result from HSVtk PCR reactions cannot distinguish between transduced target cells and VPCs, all samples that were positive for vector sequences (HSVtk) were assayed for the presence of VPC sequences (ENV). Vector producer cell sequences were detected only at the site of injection regardless of the route of administration (Table 5 ). Vector producer cell sequences were rarely detected when VPCs were injected subcutaneously with only one positive injection site specimen at both the lower and higher doses. VPCs were detected more frequently when VPCs were injected intracerebrally and the frequency of detection was dose dependent. Of the 10 animals positive for HSVtk sequences at the lower dose, two were also positive for ENV sequences while seven of nine HSVtk positive rats were positive for ENV sequences at the higher dose.
Discussion
Murine retroviral vectors have limited utility for systemic delivery in man due to the rapid inactivation via human 
serum complement. 10, 11 A decrease in titer of approximately 100-fold has been reported when murine retroviral vectors are exposed to human serum for 1 min. Furthermore, pre-existing antibodies directed towards cells of murine origin have been identified in human serum. 12 The potential for systemic distribution of either vectors or VPCs derived from murine systems, therefore, is presumed to be extremely low. At high doses of VPC or [Vector] , however, endogenous mechanisms of inactivation that limit distribution may be less efficient. Furthermore, the clone of VPCs used in these studies was previously shown to be more effective for in vivo tumor transduction than previous clones due to a 10-to 100-fold increase in titer. 13 Therefore, animal studies were conducted to assess the risk of gene transfer resulting from systemic distribution of murine retroviral vectors and vector producer cells.
Rats were injected with viable, murine retroviral VPCs or [Vector] by two different routes, subcutaneous and intracerebral, at two doses. Seven days after injection, all rats were killed and selected organs and tissues were collected for molecular analysis for the presence of vector or VPCs. The criteria used to select tissues or organs for analysis were: highly perfused tissues, highly proliferative tissues, sites of injection and gonadal tissues.
In keeping with CBER recommendations that the most sensitive methods available be employed, specific PCR assays were developed and validated. To use assays with single copy sensitivity, procedures to maximize sensitivity and minimize cross-contamination of samples and reagents as well as statistically supported retest strategies were critical. Environmental controls such as flow of materials, personnel traffic, physical separation of work and air handling systems, careful technical skills and care in the collection and handling of animal tissues were used to reduce the frequency of false positive results. The overall incidence of false positive results during validation of the HSVtk PCR assay was 0/300 for reagent controls and 1/300 for DNA spiked negative controls, for a combined false positive incidence of 0.17%.
The value of the retest strategy used in this report is demonstrated by the result that two of 165 negative control samples were positive in the first HSVtk PCR assay, while none tested positive upon retesting. This is a false positive rate of 1.4% and true positive results occurring at such low frequencies could not have been distinguished from false positive results if a retest strategy was not employed. A similar retest strategy has been used to evaluate clinical samples. 8, 9 The subcutaneous route was chosen to maximize exposure of animals to VPC or [Vector] as this would avoid rapid inactivation by serum complement. While murine retroviral vectors are sensitive to inactivation by rat serum complement, naive rat serum does not destroy murine VPCs due to an absence of pre-existing antimouse antibodies (data not shown). In addition, large volumes can be tolerated subcutaneously allowing a 100-fold higher dose over clinically anticipated doses. The subcutaneous study was designed to identify target organs for gene transfer under worst case conditions. Any tissue or organ that was identified as a target in this study was also evaluated when VPCs were injected intracerebrally.
The tissues/organs identified as targets for gene transfer based on positive HSVtk PCR results in the subcutaneous study included the site of injection and draining lymph node. Occasionally, other tissues were positive for vector sequences, but with low frequency and without dose dependence. These tissues included lung, contralateral skin and testis. The positive testis sample was obtained from a single male rat injected with VPCs at the lower dose subcutaneously. This animal also had a positive contralateral skin sample, but all other tissues were negative, including the site of injection. Although the PCR retest strategy used in this study decreases the potential of false positive results, sample contamination cannot be discounted as an explanation for this discrepant result.
We postulate that the positive draining lymph node samples are the result of gene transfer to mononuclear cells that subsequently traffic to the draining lymph node. Immune responses to VPCs and [Vector] may result in mononuclear cell infiltration and activation at the site of injection. Activated mononuclear cells would then be targets for gene transfer. Blood samples from animals with positive lymph nodes were not positive for vector sequences possibly due to the low level of transduced mononuclear cells present. Accumulation of positive mononuclear cells in the draining lymph node may increase the relative representation of transduced cells and facilitate detection in this tissue as compared with whole blood.
Vector distribution following intracerebral injection of VPC at the clinical dose was limited to the injection site. At a two-fold higher dose, in addition to the site of injection, the mandibular lymph node was occasionally positive. As previously discussed, this is believed to be the result of mononuclear cells transduced locally at the site of VPC injection that subsequently accumulate in the locally draining lymph node. Transduced peripheral blood mononuclear cells (PBMC) have been detected in patients receiving intracerebral administration of VPCs indicating that these cells are potential targets for gene transfer. 8 VPCs were not detected in any of the distal tissues or organs analyzed indicating that systemic distribution of VPCs does not occur. VPCs could be detected at the site of either subcutaneous or intracerebral injection. These data demonstrate that vector producer cell DNA persists at the site of injection for at least 7 days after administration. VPCs were detected at the site of injection more frequently when injected intracerebrally as compared with subcutaneous administration. As the central nervous system is a relatively closed space that provides some immune privilege, a delay in VPC elimination when injected intracerebrally is not unexpected. Furthermore, an increase in the frequency of detection of VPC DNA at the higher intracerebral dose suggests that VPCs are not as efficiently eliminated when administered at higher doses, possibly due to mass effects.
The frequent detection of vector in brain samples from rats injected intracerebrally at the lower dose of VPC suggests that cells in the brain have been transduced since HSVtk sequences were detected in the absence of ENV sequences. However, the identity of these transduced cells could not be ascertained in this study. Normal brain tissue is predominantly non-proliferating and therefore should be refractile to retroviral gene transfer. However, infiltration of mononuclear cells as well as activation and proliferation of host astro-and microglial cells have been reported when mouse xenografts have been implanted in adult rat brain.
14 A similar injury response is likely to have occurred as a result of injection of murine VPCs into normal rat brain. These data are interpreted as indicating that transduction of activated, non-neuronal host cells has occurred and is not believed to be of toxicological significance.
The primary concern of a positive result in whole tissue PCR of gonadal tissue is the possibility that germ cells have been transduced. Unfortunately, whole tissue PCR analyses cannot identify the cell type(s) transduced. Therefore, examination of offspring resulting from breeding positive animals has been suggested. It should be noted that the presence of retroviral vector DNA in whole testis at a level of 10 copies in 500 000 cells, the claimed sensitivity of the assay used in this report, requires examination of 50 000 offspring to have only a 0.002% probability of detection. Since a study of this scope would be technically and logistically prohibitive, while being statistically unlikely to detect a true positive if it occurred, consideration should be given to establishing thresholds for further analysis when whole tissue PCR results in a positive gonadal specimen.
In conclusion, widespread, systemic distribution of retroviral vectors was not observed when VPCs were administered either subcutaneously or intracerebrally. Vector sequences were rarely detected in tissues other than the site of injection and then at very low frequencies. These results are similar to those reported by Kamantigue et al 15 in which distribution of retroviral vectors following intramuscular administration was limited to the site of injection and draining lymph nodes. Furthermore, these data are in close agreement with data obtained from biopsy and autopsy specimens from clinical trials demonstrating the predictive value of preclinical studies for evaluating clinical risk. 9 
Materials and methods

VPCs
Murine retroviral vector producer cells (VPCs), PA317/G1Tk1SvNa.7, were manufactured at Genetic Therapy, Inc according to current Good Manufacturing Practices (cGMP) requirements. Product lots used in these animal studies passed all quality control requirements and were certified for clinical use. Cells were packaged in 4 ml vials and stored in the vapor phase of liquid nitrogen until processing before administration. Vials were thawed in a 37°C water bath, the cells removed and slowly resuspended in 50 ml of PlasmaLyte A (PLA; Baxter, Deerfield, IL, USA). Cells were washed three times in PLA to remove serum and DMSO, then resuspended in PLA to a final concentration of 1-2 × 10 8 cells/ml. Cell viability ranged from 78-85% following processing. Vector supernatant derived from the VPC product lots used in these studies had a G418 titer of 2-4 × 10 6 cfu/ml.
Concentrated vector
The PA317/G1Tk1SvNa.7 VPCs produce the G1Tk1SvNa.7 vector. This vector contains the thymidine kinase (HSVtk) gene from Herpes simplex virus and the gene that encodes resistance to the neomycin analogue, G418, abbreviated as Na, which is under transcriptional control of the SV40 viral promoter/enhancer (Sv). The G1Tk1SvNa.7 vector was concentrated by tangential flow filtration as previously described. 16 The concentrated vector had a titer of 1 × 10 7 cfu/ml as measured by titering on NIH/3T3 mouse fibroblasts and counting G418 resistant colonies. Concentrated vector is indicated as [Vector] throughout the remainder of this report.
VPC and [Vector] administration
All animal use was reviewed and approved by the Institutional Animal Care and Use Committee before initiation. These studies were performed in compliance with the Animal Welfare Act and all applicable guidelines, regulations and institutional policies. Seven to 8-week-old Fisher 344 rats were acclimated for a minimum of 1 week and randomly assigned to treatment groups ( Table 1 ). The average weight of male and female rats at the time of treatment was 140 g and 122 g, respectively. For subcutaneous inoculation, rats were lightly anesthetized using isofluorane inhalation. The animal was prepared for injection by shaving the right flank and disinfecting the area to be injected with alcohol. VPCs or [Vector] were injected at two doses. The doses chosen were based on extrapolations from clinical doses anticipated to be used in humans (see below). When ambulatory, rats were returned to their cage and observed daily. Seven days after injection, rats were killed and selected tissues and organs were collected.
For intracerebral administration rats were deeply anesthetized with ketamine (80 mg/kg) and xylazine (8 mg/kg), and placed in a stereotactic frame (Kopf, Tujunga, CA, USA) as described by Culver et al. 17 After shaving the head, the exposed skin was disinfected using iodine swabs (Povidone; Professional Disposables, Orangeburg, NY, USA) and a 1-2 cm midline incision was made extending from the eyes to just behind the ears. The skin and underlying muscle was retracted and using a Dremel (Racine, WI, USA) drill and small carbide drill bit, a 2 mm diameter hole was drilled through the skull at a position 2.5 mm to the right of midline and 3 mm anterior to the saggital suture. A 23-gauge needle was inserted 4 mm into the brain and VPCs were slowly injected using a Hamilton syringe, which was left in place for 4 min before it was slowly withdrawn. Two doses of VPCs were injected using brain weight to body weight scaling methods described below. The skin was closed with n-butyl cyanoacrylate (Nexaband; Tri-Point Medical LP, Raleigh, NC, USA) and the animals were placed on a heating pad until ambulatory at which time they were returned to their cage and observed daily. Seven days after injection, rats were killed and selected tissues and organs were collected.
Dose calculations
Subcutaneous injection doses were calculated using the premise that the maximum human clinical dose of VPCs would be 5 × 10 8 cells per patient and the maximum clinical dose of [Vector] would be 2 × 10 8 c.f.u. per patient. Using an average body weight of 60 kg for man, rat doses of 8.3 × 10 6 cells/kg and 3.3 × 10 6 cfu/kg were calculated and identified as the 1× doses for VPCs and [Vector], respectively. A 100-fold higher dose of each material was also used for subcutaneous administration and was accomplished by injecting a 100-fold higher dose volume, which was easily accommodated in the subcutaneous location.
Due to significant differences in the ratio of brain weight to body weight for different species, doses for intracerebral administration of VPCs were based on brain weight rather than body weight. Based of an average brain weight 1330 g for a 70 kg man, 18 a clinical dose of 1 × 10 9 VPCs per patient is equivalent to a dose of 7.5 × 10 5 cells/g brain. This was identified as the 1× dose for intracerebral injections. Brain weights for rats were estimated from body weights using the conversion of 1 g brain per 100 g total body weight. 19 The 1× dose was administered using VPC preparations at a concentration of 1 × 10 8 cells/ml and dose volumes that did not exceed 30 l. Unlike subcutaneous administration, the volume that can be administered intracerebrally is more limited. To achieve a higher dose, VPCs were prepared at a twofold higher concentration, 2 × 10 8 cells/ml. VPCs could not be prepared at concentrations greater than 2 × 10 8 cells/ml without a significant loss of viability. Therefore, a two-fold increase in dose was the highest achievable dose for intracerebral administration.
Tissue collection
Twelve different tissues or organs were collected from all rats under sterile conditions. To minimize potential crosscontamination of tissues, tissue collection was performed in laminar flow biosafety cabinets. Separate instruments, including scalpel blades and handles, forceps, scissors and needles were used for each tissue collected. To prevent animal to animal contamination, only one animal was necropsied at a time. The tissues or organs collected were skin and subcutaneous tissue (from right flank, the site of injection and left flank, the contralateral uninjected side), brain (a coronal section through the site of injection), inguinal lymph nodes (right and left), mandibular lymph node, blood, bone marrow, liver, kidney, jejunum, heart, lung and gonads (testis or ovary). Tissues were placed in sterile polypropylene tubes, immediately frozen on dry ice and stored at −80°C until molecular analyses were performed.
DNA isolation
DNA from all tissues was isolated using the Qiagen Blood and Cell Culture DNA Midi Kit (Qiagen, Chatsworth, CA, USA). Frozen tissues (with the exception of whole blood) were thawed and minced using sterile disposable scalpels. Minced tissues were lysed by incubation overnight at 55°C in Qiagen buffer G2 containing 0.2 mg/ml RNAseA and 0.1 mg/ml Proteinase K. Lysates were vortexed briefly and then applied to Qiagen-tip 100 columns. Columns were washed and DNAs were eluted as described in the manufacturer's instructions. After precipitation, DNAs were dissolved in water at a concentration of у0.22 g/l and stored at −80°C. Whole blood samples were thawed and treated with Qiagen buffer C1 to lyse cells and preserve the nuclei. The nuclei were pelleted, washed and then lysed by incubation in Qiagen buffer G2 containing 0.4 mg/ml of Proteinase K for 45-60 min at 55°C. The lysates were then applied to Qiagentip 100 columns and processed as described above.
PCR assays
The HSVtk PCR assay, which amplifies a 740 bp fragment of the HSVtk gene, was performed as previously described. 8 Briefly, amplification was performed in a reaction volume of 100 l under the following conditions: 3.3 g sample DNA (approximately 500 000 cell equivalents), 0.5 m of each primer, 1.25 mm MgCl 2 , 1× AmpliTaq PCR Buffer (PE Applied Biosystems, Foster City, CA, USA), 0.2 mm dNTPs, 1 unit Perfect Match Enhancer (Stratagene, La Jolla, CA, USA) and 5 units AmpliTaq polymerase (PE Applied Biosystems). Products were amplified by 50 cycles of successive incubations at 94°C for 1 min, 65°C for 1 min, and 72°C for 2 min. Amplification cycles were then followed by a 10 min extension at 72°C and a 4°C hold. The HSVtk primer sequences were: 5Ј primer: 5Ј-CACTCCTTCTCTAGGCGCCGGAAT-3Ј 3Ј primer: 5Ј-GGTCGATGTGTCTGTCCTCCGGAA-3Ј Amplification products were analyzed by gel electrophoresis followed by blotting on to Magnagraph nylon membrane (Micron Separations Inc, Westboro, MA, USA) and UV crosslinking. Hybridization to a radiolabelled synthetic oligo probe (5Ј-32 P-TTTATATAGACGGTCCTC ACGGGATGGGGAAAACCACCA-3Ј) was carried out at 55°C for 18-48 h followed by two 15-min washes in 0.1× SSC/0.5% SDS at room temperature and a 1 h wash in 0.1× SSC/0.5% SDS at 37°C. Membranes were subsequently exposed to phosphor-screens and analyzed on the Storm 840 Imaging System (Molecular Dynamics, Sunnyvale, CA, USA).
The ENV PCR assay amplifies a 713 bp region of the retroviral envelope sequences contained in pPAM3, the packaging sequences present in PA317 cells. 20 The amplification conditions were as described for the HSVtk PCR assay with the substitution of 1.5 mm MgCl 2 . The products were amplified by incubation at 80°C for 2 min and 94°C for 1 min followed by 45 cycles of incubations at 94°C for 1 min, 60°C for 30 s, and 72°C for 45 s +1 s per cycle. Amplification cycles were then followed by a 10-min extension at 72°C and a 4°C hold. Products were analyzed as previously described for HSVtk PCR using a probe specific for the ENV amplification product: (5Ј-32 P-CAAGGATGGTTCGAAGGGCTGTTTAATAGATCCCC CTGGT-3Ј). A schematic representation of the vector and packaging plasmids with positions of the primers used for PCR detection of vector (HSVtk) and VPC (ENV) sequences are shown in Figure 1 .
Sensitivity of PCR assays
To determine the reproducibility and sensitivity of the PCR methodology used in these studies, validations were done in which one and 10 target DNA copies were spiked into the quantity of DNA equivalent to 500 000 human cells (3.3 g) . The results of the HSVtk PCR validation study are shown in Table 2 . For negative controls, which consisted of either assay reagents only (no DNA) or unspiked negative DNAs, no false positive was observed in 300 reagent controls and only one false positive was detected in a total of 300 negative DNA samples (0.33%). In samples spiked with an average of one target DNA molecule, 205 of 300 specimens (68.3%) tested positive, which is not statistically different from the value predicted by Poisson distribution (P Ͼ 0.2, Yates-corrected chi square test). There was no tissue-specific inhibition of PCR in any of the 15 tissue types evaluated.
These results demonstrate that this assay is able to detect a single target molecule if present. However, this level of assay sensitivity is associated with an unacceptably high probability of obtaining a false negative result (36.8%). Therefore, an assay sensitivity of 10 or greater target DNA copies per 500 000 cells has been claimed. This lowers the probability of obtaining a false negative result due to sampling error to less than 0.01% with Ͼ99.9% confidence of detection. This high confidence level predicted by the Poisson distribution was consistent with assay performance: 299 of 300 (99.67%) samples spiked with an average of 10 target DNA copies tested positive. A similar validation was performed for the ENV PCR assay with comparable sensitivity and specificity. 
PCR strategy
False positives are a recognized outcome in PCR assays developed for detection of low copy number targets. Methods to minimize false positive results included stringent methods for tissue collection, dedicated rooms for DNA isolation and reaction set-up, a separate air handling system and a PCR retest strategy to confirm all positive results. Briefly, all samples were first analyzed for the presence of HSVtk sequences. Any positive test was confirmed in a second HSVtk PCR assay using the same DNA preparation. Only samples testing positive in both first and second HSVtk PCR assays were scored as positive for the presence of vector. Samples positive for HSVtk were further tested for the presence of ENV. Samples testing positive for ENV in two assays were scored as positive for VPCs. This retesting strategy is statistically valid due to the low false negative rate (0.01%) associated with either of these assays and only reduces the probability of detection of a true positive from 99.99% to 99.98% at a claimed sensitivity of 10 vector copies in 500 000 cell equivalents.
